Boehringer Ingelheim International GmbH

General information
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein, Rhineland-Palatinate

Contact person: Harro Ten Wolde, Head of Global Media Relations
Company main phone: +49 (6132) 770
Company main fax:  +49 (6132) 720
Year founded:1885
Source of foundation:Independent foundation
Name of foundation source:Founded by Mr. Albert Boehringer
No. of employees: Worldwide:  53000
Corporate description / mission:
Boehringer Ingelheim International GmbH researches, develops, manufactures and markets human and veterinary pharmaceutical products. The company's product Aptivus® indicated for combination antiretroviral treatment of HIV-1-infected patients, co-administered with 200 mg of ritonavir, who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor. The company's another product Atrovent® is used for the prevention and treatment of shortness of breath in patients with chronic obstructive pulmonary disease (COPD) and mild to moderate bronchial asthma in adulthood and childhood as a supplement to beta-agonists in cases of acute asthma.
State of ownership: Private / independent
Headquarters: HQ: Yes
Remarks on ownership / listings
Boehringer Ingelheim GmbH was formerly known as Boehringer Ingelheim Zentrale GmbH and changed its name to Boehringer Ingelheim GmbH in 1989.
  • Pharma (fully integrated)
  • Anti-infectives
  • Antibodies
  • Nucleic acid drugs
  • Peptides
  • Proteins
  • Vaccines
Primary therapeutic areas:
  • Cardiovascular / cardiology
  • Digestive system / gastroenterology
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the eye / ophthalmology
  • Diseases of the nervous system / neurology
  • Endocrine, nutritional and metabolic diseases / endocrinology
  • External causes of morbidity and mortality / traumatology
  • Genitourinary system / Urology
  • Infectious and parasitic diseases / infectiology / parasitology
  • Mental and behavioural disorders / psychiatry /psychology
  • Musculoskeletal system and connective tissue / Orthopedics
  • Neoplasms / cancer / oncology
  • Respiratory / pulmonology
  • Skin and subcutaneous tissue / dermatology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • In-licensing
  • Manufacturer
  • Out-licensing
  • R&D
  • Supplier / Distributor
Customer segments:
  • Hospitals
  • Large biotech & big pharma
  • Physicians / doctors
  • Small biotech
  • Direct (own sales force)
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Number of Biotech Products
Phase I:31
Phase II:23
Phase III:10
On the market:15
Description of products:
Spesolimab, etc.
Collaborations & Clients
Partnering strategy / collaborations:
Institute of Molecular Pathology (IMP)
Institute of Molecular Biology (IMB)
University of Applied Sciences in Biberach, Germany
University of Ulm, Germany
Technische Universität Dresden, etc.